Agenda
- Overview of Pancreatic Cancer
- Optimal Treatment Approach for Newly Diagnosed Advanced Pancreatic Cancer
- Selecting Treatment for Patients With Advanced Pancreatic Cancer Who Progress After Initial Therapy
- Management of Adverse Events
- Future Directions in Advanced Pancreatic Adenocarcinoma
Events
Date / Time
Event Details
7/26/2018
8:00 AM
San Antonio, TX
Audie L. Murphy Memorial VA Hospital
Details
8/17/2018
9:00 AM
Brooklyn, NY
VA New York Harbor Healthcare System - Brooklyn Campus at SUNY Downstate
Details
Faculty
Co-Chair
Thomas H. Cartwright, MD
Associate Professor of Medicine
University of Central Florida School of Medicine
Orlando, Florida
US Oncology GI Research Committee
Ocala, Florida
Co-Chair
Milind Javle, MD
Professor
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Faculty
Tanios Bekaii-Saab, MD
Professor
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona
Faculty
Bassel F. El-Rayes, MD
Professor and Vice Chair for Clinical Research
Department of Hematology and Medical Oncology
Associate Director for Clinical Research
Director, Gastrointestinal Oncology Program
Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, Georgia
Faculty
Andrew Ko, MD
Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California
Faculty
Daniel Laheru, MD
Professor of Oncology
Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Co-Director, Gastrointestinal Cancer Program
Co-Director, Skip Viragh Center for Pancreatic Cancer Research and Clinical Care
Member, Miller-Coulson Academy of Clinical Excellence
The Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Faculty
Katrina S. Pedersen, MS, MD
Assistant Professor of Medicine
Division of Oncology
Department of Medicine
Siteman Cancer Center
Washington University School of Medicine
St Louis, Missouri
Faculty
Kenneth Yu, MD, MSc
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
New York, New York
Adjunct Assistant Professor
Department of Pharmacology
University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Fellow
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York
CME
Program Overview
Experts present optimal treatment strategies for patients with pancreatic cancer in an interactive 1-hour live workshop at VHA centers, with a downloadable summary resource guide and affiliated slideset.
Target Audience
This program is intended for physicians, registered nurses, and other healthcare professionals working within the VHA system who care for patients with pancreatic cancer.
Goal Statement
The goal of this activity is to improve participants’ competence and performance in selecting and applying optimal therapeutic strategies for veterans with newly diagnosed or relapsed/refractory pancreatic cancer.
Learning Objectives
- Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed advanced pancreatic cancer
- Compare first-line gemcitabine and albumin-bound paclitaxel combination therapy vs FOLFIRINOX chemotherapy for patients with stage IV pancreatic cancer
- Plan treatment strategies for patients with advanced pancreatic cancer after progression on gemcitabine-based induction therapy based on available data and treatment guidelines
- Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer
- Nurses will be able to provide appropriate care and counsel for patients and their families
Accreditation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.